Q32 Bio (QTTB) Capital Expenditures Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 143.40% |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | -29.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.15% |
| Dec 31, 2025 | 282.35% |
| Jun 30, 2025 | -210.76% |
| Mar 31, 2025 | 114.78% |
| Sep 30, 2024 | 238.22% |
| Jun 30, 2024 | 16.75% |
| Mar 31, 2024 | 2,200.00% |
| Sep 30, 2023 | -3,283.33% |
| Jun 30, 2023 | -84.23% |
| Mar 31, 2023 | -91.53% |
| Dec 31, 2022 | -95.65% |
| Sep 30, 2022 | 110.00% |
| Jun 30, 2022 | 267.50% |
| Mar 31, 2022 | -92.78% |
| Dec 31, 2021 | 107.76% |
| Sep 30, 2021 | -138.22% |
| Jun 30, 2021 | -132.63% |
| Mar 31, 2021 | 101.73% |
| Dec 31, 2020 | -1,075.33% |
| Sep 30, 2020 | 101.00% |
| Jun 30, 2020 | -80.06% |
| Mar 31, 2020 | -92.32% |
| Dec 31, 2019 | -101.42% |
| Sep 30, 2019 | -425.45% |
| Jun 30, 2019 | 167.28% |
| Mar 31, 2019 | 19,433.33% |
| Dec 31, 2018 | 4,630.72% |
| Sep 30, 2018 | 227.22% |
| Jun 30, 2018 | 692.42% |
| Mar 31, 2018 | -96.82% |